NORCROSS, Ga.--(BUSINESS WIRE)--SpectRx, Inc. (OTCBB: SPRX) announced it has held its preliminary premarket approval application (PMA) meetings with the U.S. Food and Drug Administration. The meetings were designed to ensure the data, data format and supporting documentation of a PMA application will meet standards and expectations of the agency and its advisory panel.
